Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort
Key Points
Ocrelizumab shows a greater impact on reducing smoldering activity compared to teriflunomide, suggesting different therapeutic benefits.
Participants in the study showed varied responses to both drugs, emphasizing the importance of personalized treatment approaches.
Observational study utilizing data from the Swiss Multiple Sclerosis Cohort to assess treatment effectiveness across different cases.
Significant findings support the need for further exploration into the efficacy of these treatments in diverse populations.
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort | Synapse